It also does not produce sterile injectable oncology products Solu-Cortef (hydrocortisone sodium succinate for injection), and Solu-Medrol (methylprednisolone sodium succinate for injection) there. In June, Pfizer notified the FDA and its customers that it will soon have limited supply on certain Bicillin formulations. Select formulations of Bicillin L-A (penicillin G benzathine) and Bicillin C-R (penicillin G benzathine and penicillin G procaine) prefilled syringes are expected to be in limited supply and out-of-stock, Pfizer said. The supply interruption is the result of "a complex combination of factors, including significant increases in demand, an increase in syphilis infection rates, as well as competitive shortages," Pfizer said in the letter. The Pfizer plant damage underscores the need for reform in drug manufacturing to prevent future drug shortages, according to the American Society of Health-System Pharmacists.